In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering:

• 
  The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche.
  


• 
  How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side.
  


• 
  How Fujifilm’s culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised.
  


• 
  Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating.
  


• 
  Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain.
  

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. 
 

Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan. 
 
Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies’ global facilities regardless of geographical differences.
 
Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master’s degree from the Technical University of Denmark.

 
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!